Purpose: The purpose of this study was to evaluate the relationship between obstructive sleep apnea syndrome (OSAS) and glaucoma progression, and to examine the correlation between OSAS severity and rate of visual field (VF) loss.
O bstructive sleep apnea syndrome (OSAS) is a disorder of sleep and breathing that features recurrent episodes of apnea or hypopnea because of the collapse of upper airway tissues. 1 Apneic or hypopneic episodes often induce significant hypoxemia that can have deleterious effects on the cardiovascular system, leading to hypertension, cardiomyopathy, arrhythmias, or heart failure. 1, 2 OSAS is most often diagnosed with polysomnography (PSG), the simultaneous recording of sleep, airflow, respiratory effort, and oxyhemoglobin saturation conducted while attended in a sleep testing facility. Patients are classified as mild, moderate, or severe OSAS based on an Apnea-Hypopnea Index (AHI), 3 a frequency metric derived from the sum of apnea and hypopnea events divided by the total sleep time in hours. Treatment often consists of continuous positive airway pressure (CPAP) devices.
There has been considerable interest in the potential relationship between OSAS and various ophthalmic conditions, such as floppy eyelid syndrome, 4 ,5 keratoconus, 6, 7 papilledema, 8 optic neuropathy, 9 and glaucoma. 10 Given its effects on vasculature, 11, 12 OSAS is hypothesized to exacerbate glaucomatous optic neuropathy because of repeated episodes of nocturnal hypoxia adversely affecting retinal ganglion cells. However, a causal mechanism has not been clearly identified. A recent study conducted in nonglaucomatous Japanese patients has suggested that nocturnal intraocular pressure (IOP) decreases during apneic periods. 13 Prior studies suggest that low ocular perfusion pressure (OPP), particularly low diastolic perfusion pressure, is a major risk factor for glaucoma onset and progression. 14, 15 There is conflicting data regarding the relationship between OSAS and glaucoma. Some studies have suggested a strong link between the 2, with a prevalence of glaucoma ranging from 3% to 27%, 10, [16] [17] [18] [19] [20] while others have reported minimal or no correlation. [21] [22] [23] [24] Meta-analyses have supported an association between OSAS and the prevalence of glaucoma, 16 ,25 yet other large retrospective and prospective studies have demonstrated no difference in glaucoma prevalence amongst persons with OSAS compared to without OSAS. 22, 23 Glaucomatous eyes that continue to progress despite robust IOP lowering often prompts clinicians to pursue ancillary diagnostic testing to identify systemic disorders, such as OSAS, that could potentially influence the course of progressive glaucomatous vision loss. Although IOP remains the only modifiable risk factor in glaucoma, various IOP-independent factors have been proposed including nocturnal hypotension, 26, 27 low cerebrospinal fluid (CSF) pressure, [28] [29] [30] [31] and OSAS.
To our knowledge, no prior studies have examined the association between glaucoma progression and OSAS. The purpose of this study was to evaluate the relationship between OSAS and glaucoma progression, and to examine the correlation between OSAS severity and the rate of visual field (VF) loss.
PATIENTS AND METHODS

Study Population
A retrospective cross-sectional study was conducted to identify study patients from an electronic medical record database between January 1, 2010 and December 31, 2015. The study period was selected based upon the time period during which all Ophthalmology and Pulmonary records were available in the University of Miami electronic health record. Approval was obtained from the Institutional Review Board of the University of Miami Miller School of Medicine, and the study complied with the tenets of the Declaration of Helsinki. Patients with concurrent ICD-9 or ICD-10 diagnoses of OSAS and open-angle glaucoma were identified from an electronic database. All eyes had glaucomatous optic neuropathy defined as narrowing of the neuroretinal rim, notching, excavation, optic disc hemorrhage, or retinal nerve fiber layer defect, and reproducible VF loss defined as an abnormal pattern SD (P < 0.05) and glaucoma hemifield test outside normal limits (P < 1%). Enrollment criteria consisted of age ≥ 40 years, a minimum of 5 reliable (fixation loss <20%, false positive and negative responses <33%) VF exams [Swedish Interactive Threshold Algorithm (SITA) standard 24-2 strategy, Humphrey Field Analyzer 750 II-I, Carl Zeiss Meditec Inc., Dublin, CA], a minimum of at least 2 years of longitudinal follow-up, and a polysomnography (PSG) examination conducted within 12 months of the final VF that was used to determine the VF progression classification. One eye per-patient meeting enrollment criteria was included; if both eyes met inclusion criteria the study eye was randomly selected. Only patients with refractive error between −7D and +3D were included in this study. Exclusion criteria consisted of ocular disease other than cataract or glaucoma, anterior or posterior segment pathology that could affect visual field performance, or surgical intervention during the study period.
Polysomnography Examination
All patients had a PSG examination performed at the University of Miami Miller School of Medicine Sleep Disorders Center. The facility is accredited by the American Academy of Sleep Medicine (AASM) and PSG's were conducted, recorded and scored in accordance with AASM standards. 32 A 3% decline in SpO 2 and/or an arousal associated with a ≥ 30% reduction in airflow lasting at least 10 seconds was required to identify hypopnea. Uncalibrated respiratory inductive plethysmography was used as the sensor for determining respiratory effort. All PSG studies were conducted within 12 months of final VF used to classify patients as progressors or nonprogressors. OSAS outcome measures collected from the PSG examination consisted of AHI, body-mass index (BMI), average SpO 2 , time of SpO 2 < 88%, and SpO 2 nadir. OSA was categorized into mild (AHI ≥ 5 and <15), moderate (AHI ≥ 15 and <30), and severe (AHI ≥ 30) . 3 A subset of patients fitted with continuous positive airway pressure (CPAP) therapy was identified, and IOP measurements after CPAP initiation were collected. Compliance data stored on a CPAP smart card reflecting the usage during a consecutive 30-day interval was analyzed to quantify adherence.
Data Collection Procedures
Systemic vascular risk factors (eg, diabetes, blood pressure, history of heart disease) and ocular characteristics [visual acuity, intraocular pressure (IOP), prior optic disc hemorrhage] were abstracted from the medical record. The use of systemic antihypertensive medication and systemic β-blocker medication was collected. The number and class of glaucoma medication were recorded, as well as any history of glaucoma surgery. Glaucoma severity was categorized using the Hodapp-Parrish-Anderson grading scale 33 based upon the severity of VF loss and proximity to central fixation (early stage as VF MD > −6 dB, moderate as MD −6 to −12 dB; severe as MD <−12 dB). IOP was measured using Goldmann applanation tonometry; IOP at the first visit was deemed as baseline, whereas the mean of all IOPs at subsequent visits during the study period was deemed mean follow-up IOP. Changes in medical treatment were allowed at the discretion of the treating physician; these were not considered exclusion criteria. No laser or incisional surgery were performed during the course of the study. Mean ocular perfusion pressure (MOPP) was calculated using the equation MOPP = 2/3* [DBP+1/3*(SBP−DBP)] −IOP. 34 Diastolic perfusion pressure (DPP) was calculated using the equation DPP = DBP−IOP.
Eyes were classified as "progressors" or "nonprogressors" based upon Glaucoma Progression Analysis (GPA) criteria (Carl Zeiss Meditec Inc., Dublin, CA). GPA uses statistical criteria designed for the Early Manifest Glaucoma Trial and compares the locations on pattern deviation change probability map on follow-up visual fields to the average of 2 baseline exams. 35 An automated analysis identifies points that show change greater than the expected variability in pattern deviation (at the 95% significance level). Progression was defined as a significant change detected in ≥ 3 points, and repeated in the same points in 3 consecutive follow-up tests, categorized by the GPA software as "Likely Progression."
Statistical Analysis
Participants classified as progressors were compared with those not classified as progressors with exact permutation tests for proportions and with 2-tailed 2-sample t tests for interval level variables. Pearson correlations were calculated to assess the strength of relationship between PSG parameters and the slopes of VF mean deviation (MD), pattern standard deviation (PSD), and visual field index (VFI). In our study, we had 80% power to observe r = 0.53, which can be interpreted as a sleep parameter explaining 28% of the variability in VF slope. Logistic regression analyses were performed to estimate the odds ratios associated with sleep parameters and risk of VF progression.
RESULTS
A total of 141 patients with concurrent OSAS and glaucoma were identified from an electronic database during the study period. About 116 patients were excluded who did not have the requisite number of reliable VF exams to assess for glaucoma progression (103/116, 89%) or did not have a PSG examination performed at the University of Miami (13/s116, 11%). Twenty-five patients (mean age 67.9 ± 7.6 y) with OSAS (8 mild, 8 moderate, 9 severe) were enrolled in this investigation. Eleven of 25 (44%) eyes were classified as progressors; 14 eyes (56%) were classified as nonprogressors.
The characteristics of the study population are summarized in Table 1 . Progressors had significantly (P = 0.03) more severe baseline VF loss compared to nonprogressors as judged by the Hodapp-Parrish-Anderson classification. All other clinical characteristics including age, mean length of follow-up, IOP (baseline, mean, and peak), and central corneal thickness were similar between the groups (P > 0.05). Notably, IOP measurements (baseline, mean, and peak IOP) and IOP reducing therapy (medical and surgical) were similar between the 2 groups. Table 2 describes baseline vascular characteristics of the study population. Progressors and nonprogressors had similar (P > 0.05) arterial blood pressure, OPP, and vascular risk factors including treatment for diabetes and hypertension. Table 3 We examined the correlation (Table 4) between PSG parameters and the rate of change in VF MD, PSD, and VFI to evaluate any potential relationship between the OSAS severity and the rapidity of glaucomatous VF change. No statistically significant correlations were identified between AHI and mean MD, PSD, or VFI (Fig. 1) . The strongest correlation was between MD slope and AHI, r = −0.271 and a 95% confidence interval around it ranges from −0.60 to +0.14. Thus, if AHI is related to MD slope, it likely explains less than ≤ 36% of the variability in VF loss. We also calculated odds ratios to assess the risk of classification as a progressor based on clinically meaningful differences in each of the interval level variables. Compared with nonprogressors, the odds ratio of being a progressor: A subset of eyes consisting of 6 of 11 (54%) progressors and 7 of 14 (50%) nonprogressors were fitted for CPAP therapy after the baseline PSG examination. The mean IOP after initiation of CPAP therapy in progressors (14.2 ± 3.3 mm Hg) and nonprogressors (13.9 ± 2.7 mm Hg) was similar (P = 0.85) during the course of follow-up (mean 1.3 y after CPAP initiation). Among those with CPAP compliance data, the device was used 89.4 ± 15.3% of the time during a 30-day period with a mean residual AHI of 4.12.
DISCUSSION
Glaucoma is a progressive disorder characterized by structural and functional abnormalities of the optic nerve. 1, 36, 37 Even though IOP is the most important modifiable risk factor for disease onset and progression, [38] [39] [40] [41] [42] glaucoma can exist even among individuals for whom IOP measurements are within the statistically defined "normal range," [43] [44] [45] [46] suggesting non-IOP dependent mechanisms of optic nerve injury. These may include impaired optic nerve perfusion because of nocturnal hypotension 47 producing low OPP 14, 15, 27, 48, 49 and low CSF pressure 28, 31, 50 OSAS has been proposed as a potential risk factor for open-angle glaucoma (OAG), and in particular OAG at normal IOP. 19, 51, 52 It has been suggested that repeated intermittent periods of hypoxia might influence the development of ganglion cell loss. Lin et al suggested that normal-tension glaucoma (NTG) was correlated with moderate to severe OSAS, 18 whereas a prospective study by Bilgin found a higher rate of NTG among patients with moderate-severe OSAS. 53 In contrast, Stein et al 22 demonstrated no increased risk of NTG or primary open-angle glaucoma among a cohort of over 150,000 OSAS patients. To our knowledge, the present study is the first that seeks to examine the relationship between OSAS and glaucoma progression.
The results of the present study do not support a strong relationship between OSAS and glaucoma progression. We found that progressors and nonprogressors had similar PSG characteristics including BMI, AHI and SpO 2 metrics. We also found that OSAS severity, as determined by AHI, was not correlated with the rates of VF loss based upon the slope of MD, PSD, or VFI. Progressors and nonprogressors were similar with respect to other potential confounding factors that could otherwise influence the risk of glaucoma progression including age, IOP control during follow-up, CCT, vascular risk factors including OPP, and the severity of glaucomatous VF loss judged by MD and PSD. It is noteworthy, however, that based upon the HAP classification, which also considers the location of the glaucomatous scotoma relative to central fixation, progressors had more severe VF loss at baseline. Finally, topical medications such as brimonidine and timolol have been found to influence the rate of VF progression in NTG eyes. 15 In the present study, progressors and nonprogressors were similar with respect to the proportion of eyes receiving these medication classes.
There are reports that suggest a potential deleterious effect of CPAP therapy on IOP. Some reports speculate that CPAP equipment, which is placed along the nasal bridge in order to treat both the nasopharynx and oropharynx, may actually induce mechanical pressure on the eyes, causing IOP elevation. One prospective study showed that CPAP use was associated with greater nocturnal IOP fluctuation and absolute IOP, with a significant decrease in IOP with cessation of CPAP therapy. 54 However, more recent studies have confirmed nocturnal IOP elevation in OSAS, but have found no difference between CPAP and non-CPAP treatment groups. 22, 55 Chen et al 56 found that in their study, there was a higher rate of glaucoma among OSAS patients, but this increased risk was not mitigated by medical or surgical therapy for OSAS. Nasal CPAP has been shown to restore normal nyctohemeral IOP patterns, which may be lost in OSAS. 57 In our study, the mean IOP after initiation of CPAP therapy in progressors and nonprogressors was similar during the course of follow-up. Among those with measurements, CPAP compliance was high. In a subset of patients (6 progressors, 7 nonprogressors), CPAP therapy was initiated within 9 months before the final visual field. Given the short duration of CPAP therapy and the use of approximately 4.5 years of visual field data to assess progression, we do not believe this short use of CPAP would have confounded the determination of progression.
Our analysis of this dataset has potential weaknesses that include a retrospective study design and small sample size. However, stringent inclusion criteria, especially the use of GPA analyses to objectively detect progression, were utilized in hopes of rigorously studying any potential relationship, naturally leading to a smaller sample size. Almost 90% of subjects with both OSAS and glaucoma were excluded from the study because of an insufficient number of reliable visual fields required for progression analysis using the GPA algorithm. Even with our small sample size we were able to rule out a moderate to strong (r 2 ≥ 40%) association of polysomnography measurements with VF losses. In addition, our study was designed such that the PSG examination was performed within 12 months of the final VF used to classify patients based upon their VF progression status. A prospective study including PSGs would be financially intensive and potentially cost prohibitive. OSAS is a chronic condition similar to glaucoma, thus it was presumed to have been present in all subjects during the 4 years of follow-up from the initial VF. However, it is theoretically plausible that a variable dose-response relationship existed and that not all patients had manifest OSAS at the initiation of the study. This could potentially confound our assessment of the influence of OSAS on glaucomatous progression. The possibility of an underpowered study remains plausible; however, that does not preclude our ability to draw useful conclusions from the data. This is the reason we supplied 95% confidence limits around the effects we studied. These 95% confidence limits account for the sample size and are not compromised by power considerations. Our 95% confidence interval allows us to likely rule out a large effect of sleep apnea on visual field MD slope (r 2 > 36%), ruling out a strong effect, as opposed to a clinically significant one.
In summary, this study does not support a substantial increase in the risk of VF progression with OSAS. No correlation was observed between OSAS severity and rates of VF loss in glaucomatous eyes. Larger prospective studies could be considered to determine the value of diagnosing and controlling OSAS in eyes with progressive glaucomatous vision loss.
